Maxim Group restated their buy rating on shares of BIOLASE (NASDAQ:BIOL) in a report published on Friday morning, TipRanks reports. The brokerage currently has a $2.00 price target on the medical technology company’s stock.
A number of other equities analysts also recently commented on BIOL. Colliers Securities reissued a buy rating and issued a $1.15 target price on shares of BIOLASE in a research note on Monday, March 8th. Zacks Investment Research lowered BIOLASE from a hold rating to a sell rating in a research note on Tuesday, March 30th.
BIOLASE stock traded up $0.12 during trading on Friday, hitting $0.70. The company’s stock had a trading volume of 24,152,468 shares, compared to its average volume of 22,945,693. The stock’s fifty day moving average is $0.78 and its 200 day moving average is $0.70. BIOLASE has a 1-year low of $0.25 and a 1-year high of $1.51. The stock has a market capitalization of $105.25 million, a price-to-earnings ratio of -1.08 and a beta of 1.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.09 and a current ratio of 1.68.
Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in shares of BIOLASE by 1,140.0% in the first quarter. Renaissance Technologies LLC now owns 2,223,284 shares of the medical technology company’s stock worth $1,874,000 after buying an additional 2,043,984 shares during the last quarter. Northern Trust Corp lifted its position in shares of BIOLASE by 184.0% during the first quarter. Northern Trust Corp now owns 276,060 shares of the medical technology company’s stock worth $233,000 after purchasing an additional 178,839 shares during the last quarter. Geode Capital Management LLC increased its holdings in BIOLASE by 137.0% in the first quarter. Geode Capital Management LLC now owns 1,191,258 shares of the medical technology company’s stock valued at $1,004,000 after buying an additional 688,549 shares during the last quarter. BlackRock Inc. lifted its holdings in BIOLASE by 1,225.7% during the 1st quarter. BlackRock Inc. now owns 3,583,531 shares of the medical technology company’s stock worth $3,020,000 after buying an additional 3,313,213 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its position in shares of BIOLASE by 36.1% in the 1st quarter. Perkins Capital Management Inc. now owns 1,655,500 shares of the medical technology company’s stock worth $1,395,000 after acquiring an additional 439,250 shares in the last quarter. Institutional investors own 5.52% of the company’s stock.
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.
Further Reading: Insider Trading
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.